ProMIS Neurosciences (PMN)
NASDAQ:PMN
Want to see PMN full AI Analyst Report?
PMN Stock Chart & Stats
$8.12
-$0.04(-3.74%)
At close: 4:00 PM EST
$8.12
-$0.04(-3.74%)
Day’s Range― - ―
52-Week Range$6.27 - $39.75
Previous CloseN/A
Volume32.49K
Average Volume (3M)819.50K
Market Cap
$21.95M
Enterprise Value-$49.68M
Total Cash (Recent Filing)$63.85M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.20
Next Earnings
Aug 17, 2026EPS Estimate
-1.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-23.59
Shares Outstanding2,152,397
10 Day Avg. Volume1,049,009
30 Day Avg. Volume819,497
Financial Highlights & Ratios
PEG Ratio0.33
Price to Book (P/B)-9.53K
Price to Sales (P/S)0.00
P/FCF Ratio-426.74
Enterprise Value/Market Cap-2.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.21
Forecast
1Y Price Target
$32.00Price Target Upside294.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-5.3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Meaningful Equity BaseA debt-free balance sheet with roughly $60.7M of equity versus ~$67.4M in assets provides structural financial flexibility. For a clinical-stage biotech this reduces bankruptcy and interest burden risk, enabling the company to fund R&D and pursue trials without immediate leverage constraints.
Focused Antibody R&D Targeting NeurodegenerationA clear, focused therapeutic thesis—antibody candidates targeting toxic protein species in neurodegenerative diseases—offers a durable strategic advantage. Specialization can concentrate scientific expertise, improve trial design, and create differentiated assets if clinical proof-of-concept is achieved, aligning with long-term unmet medical needs.
Governance Continuity And Incentive FlexibilityRe-election of the board and approval to expand the option pool supports leadership continuity and enables equity-based retention. For a small clinical-stage firm, the ability to grant incentives is a durable operational tool to attract and retain scientific and executive talent critical to executing multi-year development programs.
Bears Say
Pre-revenue With Large Trailing Net LossesBeing pre-revenue while incurring sizeable recurring losses is a fundamental constraint: the company must rely on external funding to sustain operations and advance trials. Persistent deficits materially raise financing needs, increase execution risk, and can delay programs if capital is scarce.
Sustained Negative Operating And Free Cash FlowConsistent negative cash generation (~-$35.5M TTM) creates a structural funding gap that must be closed by financings or partnerships. Ongoing cash burn shortens runway, pressures management on timing of clinical milestones, and raises the probability of dilutive capital raises that affect long-term shareholder economics.
Dilution Risk And Historical Equity InstabilityApproval to expand the option reserve creates a durable dilution vector as the company issues equity to fund R&D and compensate staff. Historical episodes of negative equity (2022, 2025) signal prior capital shortfalls, implying that future financing may recur and dilute existing holders, affecting long-term per-share value.
ProMIS Neurosciences News
PMN FAQ
What was ProMIS Neurosciences’s price range in the past 12 months?
ProMIS Neurosciences lowest stock price was $6.27 and its highest was $39.75 in the past 12 months.
What is ProMIS Neurosciences’s market cap?
ProMIS Neurosciences’s market cap is $21.95M.
When is ProMIS Neurosciences’s upcoming earnings report date?
ProMIS Neurosciences’s upcoming earnings report date is Aug 17, 2026 which is in 67 days.
How were ProMIS Neurosciences’s earnings last quarter?
ProMIS Neurosciences released its earnings results on May 12, 2026. The company reported -$1.26 earnings per share for the quarter, missing the consensus estimate of -$1.06 by -$0.2.
Is ProMIS Neurosciences overvalued?
According to Wall Street analysts ProMIS Neurosciences’s price is currently Undervalued.
Does ProMIS Neurosciences pay dividends?
ProMIS Neurosciences does not currently pay dividends.
What is ProMIS Neurosciences’s EPS estimate?
ProMIS Neurosciences’s EPS estimate is -1.46.
How many shares outstanding does ProMIS Neurosciences have?
ProMIS Neurosciences has 2,152,397 shares outstanding.
What happened to ProMIS Neurosciences’s price movement after its last earnings report?
ProMIS Neurosciences reported an EPS of -$1.26 in its last earnings report, missing expectations of -$1.06. Following the earnings report the stock price went down -1.779%.
Which hedge fund is a major shareholder of ProMIS Neurosciences?
Currently, no hedge funds are holding shares in PMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
PMN Stock 12 Month Forecast
Average Price Target
$32.00
▲(294.09% Upside)